110 related articles for article (PubMed ID: 30848162)
1. Therapeutic Delivery of miR-143 Targeting Tumor Metabolism in Poorly Differentiated Thyroid Cancer Xenografts and Efficacy Evaluation Using
Miao Y; Zhang LF; Zhang M; Guo R; Liu MF; Li B
Hum Gene Ther; 2019 Jul; 30(7):882-892. PubMed ID: 30848162
[TBL] [Abstract][Full Text] [Related]
2. Metformin reduces glycometabolism of papillary thyroid carcinoma in vitro and in vivo.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Zhang XY; Sun ZK; Luo QY
J Mol Endocrinol; 2017 Jan; 58(1):15-23. PubMed ID: 27920093
[TBL] [Abstract][Full Text] [Related]
3. Glucose transporter 1 expression, tumor proliferation, and iodine/glucose uptake in thyroid cancer with emphasis on poorly differentiated thyroid carcinoma.
Grabellus F; Nagarajah J; Bockisch A; Schmid KW; Sheu SY
Clin Nucl Med; 2012 Feb; 37(2):121-7. PubMed ID: 22228332
[TBL] [Abstract][Full Text] [Related]
4. Correlation of BRAFV600E Mutation and Glucose Metabolism in Thyroid Cancer Patients: An ¹⁸F-FDG PET Study.
Nagarajah J; Ho AL; Tuttle RM; Weber WA; Grewal RK
J Nucl Med; 2015 May; 56(5):662-7. PubMed ID: 25814520
[TBL] [Abstract][Full Text] [Related]
5. MiR-128 suppresses the growth of thyroid carcinoma by negatively regulating SPHK1.
Cao XZ; Bin H; Zang ZN
Biomed Pharmacother; 2019 Jan; 109():1960-1966. PubMed ID: 30551451
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value and therapeutic impact of (18)F-FDG-PET/CT in differentiated thyroid cancer. Results of a German multicentre study.
Riemann B; Uhrhan K; Dietlein M; Schmidt D; Kuwert T; Dorn R; Sciuk J; Kodalle T; Schober O
Nuklearmedizin; 2013; 52(1):1-6. PubMed ID: 23192295
[TBL] [Abstract][Full Text] [Related]
7. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
Salvatori M; Biondi B; Rufini V
Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
[TBL] [Abstract][Full Text] [Related]
8. MiR-20b Displays Tumor-Suppressor Functions in Papillary Thyroid Carcinoma by Regulating the MAPK/ERK Signaling Pathway.
Hong S; Yu S; Li J; Yin Y; Liu Y; Zhang Q; Guan H; Li Y; Xiao H
Thyroid; 2016 Dec; 26(12):1733-1743. PubMed ID: 27717302
[TBL] [Abstract][Full Text] [Related]
9. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
[TBL] [Abstract][Full Text] [Related]
10. 18F-Fluorodeoxyglucose uptake on positron emission tomography/computed tomography is associated with metastasis and epithelial-mesenchymal transition in hepatocellular carcinoma.
Lee M; Jeon JY; Neugent ML; Kim JW; Yun M
Clin Exp Metastasis; 2017 Apr; 34(3-4):251-260. PubMed ID: 28429188
[TBL] [Abstract][Full Text] [Related]
11. (18)F-FDG PET/CT for Monitoring the Response of Breast Cancer to miR-143-Based Therapeutics by Targeting Tumor Glycolysis.
Miao Y; Zhang LF; Guo R; Liang S; Zhang M; Shi S; Shang-Guan CF; Liu MF; Li B
Mol Ther Nucleic Acids; 2016 Aug; 5(8):e357. PubMed ID: 27574783
[TBL] [Abstract][Full Text] [Related]
12. Down-Regulated miR-125a-5p Promotes the Reprogramming of Glucose Metabolism and Cell Malignancy by Increasing Levels of CD147 in Thyroid Cancer.
Huang P; Mao LF; Zhang ZP; Lv WW; Feng XP; Liao HJ; Dong C; Kaluba B; Tang XF; Chang S
Thyroid; 2018 May; 28(5):613-623. PubMed ID: 29634399
[TBL] [Abstract][Full Text] [Related]
13. Monitoring response to gefitinib in nude mouse tumor xenografts by (18)F-FDG microPET-CT: correlation between (18)F-FDG uptake and pathological response.
Zhou LN; Wu N; Liang Y; Gao K; Li XY; Zhang LF
World J Surg Oncol; 2015 Mar; 13():111. PubMed ID: 25888731
[TBL] [Abstract][Full Text] [Related]
14. Postoperative fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography: an important imaging modality in patients with aggressive histology of differentiated thyroid cancer.
Nascimento C; Borget I; Al Ghuzlan A; Deandreis D; Hartl D; Lumbroso J; Berdelou A; Lepoutre-Lussey C; Mirghani H; Baudin E; Schlumberger M; Leboulleux S
Thyroid; 2015 Apr; 25(4):437-44. PubMed ID: 25633259
[TBL] [Abstract][Full Text] [Related]
15. The miR-125a/HK2 axis regulates cancer cell energy metabolism reprogramming in hepatocellular carcinoma.
Jin F; Wang Y; Zhu Y; Li S; Liu Y; Chen C; Wang X; Zen K; Li L
Sci Rep; 2017 Jun; 7(1):3089. PubMed ID: 28596599
[TBL] [Abstract][Full Text] [Related]
16. miR-183 regulates biological behavior in papillary thyroid carcinoma by targeting the programmed cell death 4.
Wei C; Song H; Sun X; Li D; Song J; Hua K; Fang L
Oncol Rep; 2015 Jul; 34(1):211-20. PubMed ID: 26063221
[TBL] [Abstract][Full Text] [Related]
17. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
[TBL] [Abstract][Full Text] [Related]
18. Afamin promotes glucose metabolism in papillary thyroid carcinoma.
Shen CT; Wei WJ; Qiu ZL; Song HJ; Luo QY
Mol Cell Endocrinol; 2016 Oct; 434():108-15. PubMed ID: 27329154
[TBL] [Abstract][Full Text] [Related]
19. Involvement of EZH2 in aerobic glycolysis of prostate cancer through miR-181b/HK2 axis.
Tao T; Chen M; Jiang R; Guan H; Huang Y; Su H; Hu Q; Han X; Xiao J
Oncol Rep; 2017 Mar; 37(3):1430-1436. PubMed ID: 28184935
[TBL] [Abstract][Full Text] [Related]
20. Functional visceral fat activity evaluated by preoperative F-18 FDG PET/CT predicts regional lymph node metastasis in differentiated thyroid cancer.
Pahk K; Choi S; Kim S
Clin Endocrinol (Oxf); 2018 Jun; 88(6):963-968. PubMed ID: 29603322
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
